Journal article

Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER.

  • Monés J Institut de la Màcula, Barcelona, Spain; Barcelona Macula Foundation, Barcelona, Spain.
  • Srivastava SK Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Jaffe GJ Department of Ophthalmology, Duke University, Durham, North Carolina, USA.
  • Tadayoni R Departement Hospitalo-Universitaire Vision et Handicaps, Paris, France; Université de Paris, Ophthalmology Department, AP-HP, Hôpital Lariboisière, Rothschild Foundation Hospital, Paris, France.
  • Albini TA Bascom Palmer Eye Institute, The University of Miami, Miami, Florida, USA.
  • Kaiser PK Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Holz FG Department of Ophthalmology, University of Bonn, Bonn, Germany.
  • Korobelnik JF CHU Bordeaux, Service d'ophtalmologie, Bordeaux, France; Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France.
  • Kim IK Dr. Kim participated in this study as a consultant to Novartis independent of her faculty appointment in the Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
  • Pruente C Department of Ophthalmology, University of Basel, Basel, Switzerland; Department of Ophthalmology, Kantonsspital Baselland, Liestal, Switzerland; Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland.
  • Murray TG Murray Ocular Oncology and Retina, Miami, Florida, USA.
  • Heier JS Ophthalmic Consultants of Boston, Boston, Massachusetts USA. Electronic address: jsheier@eyeboston.com.
Show more…
  • 2020-11-18
Published in:
  • Ophthalmology. - 2020
English OBJECTIVE
An independent Safety Review Committee (SRC; supported by Novartis Pharma AG [Basel, Switzerland]) analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related macular degeneration (nAMD).


DESIGN
A post-hoc analysis of a subset of data from two 2-year, double-masked, multicenter, active-controlled randomized phase 3 trials (NCT02307682, NCT02434328).


PARTICIPANTS
Patients (N=1817) with untreated, active choroidal neovascularization due to AMD in the study eye were randomized and treated in HAWK/HARRIER. The SRC reviewed data from cases of investigator-reported IOI (60/1088 brolucizumab-treated eyes; 8/729 aflibercept-treated eyes).


METHODS
The SRC received details and images (color fundus photography, fluorescein angiography and optical coherence tomography) for all investigator-determined cases of IOI, retinal arterial occlusion and endophthalmitis. Cases were reviewed in detail by ≥2 readers, then adjudicated by the SRC as a group.


MAIN OUTCOME MEASURES
Within this subset of patients: incidence of IOI, signs and incidence of retinal vasculitis and/or retinal vascular occlusion, and visual acuity loss; time since first brolucizumab injection to IOI event onset; frequency of visual acuity loss following brolucizumab injection by time of first IOI event onset.


RESULTS
Fifty brolucizumab-treated eyes were considered to have definite/probable drug-related events within the spectrum of IOI, retinal vasculitis and/or vascular occlusion. Based on these cases, incidence of definite/probable IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%). There were 8 cases (incidence 0.74%) of at least moderate visual acuity loss (≥15 ETDRS letters) in eyes with IOI; 7 were in eyes with IOI + vasculitis + occlusion. Of the 8 cases, 5 experienced their first IOI-related event within 3 months of the first brolucizumab injection (increasing to 7/8 within 6 months). Incidence of IOI in aflibercept-treated eyes was 1.1%, with at least moderate visual acuity loss in 0.14%.


CONCLUSIONS
This analysis of IOI cases following brolucizumab injection identified signs of retinal vasculitis with or without retinal vascular occlusion, and an associated risk of visual acuity loss. The findings will help physicians to evaluate the risks and benefits of brolucizumab treatment for nAMD.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/264516
Statistics

Document views: 30 File downloads:
  • fulltext.pdf: 0